# A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

> **NCT02322853** · PHASE2 · TERMINATED · sponsor: **Centre Francois Baclesse** · enrollment: 8 (actual)

## Conditions studied

- Postmenopausal
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Ralimetinib (LY2228820 dimesylate)

## Key facts

- **NCT ID:** NCT02322853
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** lack of recruitment
- **Last updated:** 2017-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322853, "A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02322853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*